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Hypertension is a well-known complication in children on
renal replacement therapy and an important risk factor for
cardiovascular disease in later life. In order to define the
prevalence of and risk factors for hypertension among
children, we enrolled 3337 pediatric patients from 15
countries in the ESPN/ERA-EDTA Registry of whom 464
were on hemodialysis, 851 on peritoneal dialysis, and 2023
had received a renal allograft. Hypertension was defined
as either systolic or diastolic blood pressures in the 95th
percentile or greater for age, height, and gender or use
of antihypertensive medication. Analyses were adjusted
for age, gender, duration, and modality of renal replacement
therapy. In 10 countries in which information on the use
of antihypertensive medication was available, hypertension
was present in over two-thirds of hemodialysis, peritoneal
dialysis, or transplant patients. Blood pressure values above
the 95th percentile were significantly more prevalent in very
young patients (under 3 years) compared to 13- to 17-year
olds (odds ratio 2.47), during the first year compared to over
5 years of renal replacement therapy (odds ratio 1.80), and in
patients on hemodialysis compared to transplant recipients
or those on peritoneal dialysis (odds ratios of 2.48 and 1.59,
respectively). Over time, mean blood pressures decreased
in both hemodialysis and transplant patients, but not in
peritoneal dialysis patients. Hence, our findings highlight
the extent of the problem of hypertension in children with
end-stage renal disease in Europe.
Kidney International (2011) 80, 1092–1098; doi:10.1038/ki.2011.232;
published online 3 August 2011
KEYWORDS: blood pressure; children; dialysis; end-stage renal disease;
hypertension; transplantation
Hypertension is a frequently reported complication in
children with end-stage renal disease, with its prevalence
varying from 48 to 79% depending on the exact definition
of hypertension.1–3 In contrast to numerous studies on
hypertension and end-stage renal disease in adults,4 little
has been reported on the prevalence and treatment of hyper-
tension in the pediatric renal replacement therapy (RRT)
population in Europe. Furthermore, existing information is
usually limited to hemodialysis (HD) and peritoneal dialysis
(PD) patients, whereas information on transplanted patients
is scarce and comes from single-centre experiences.5
The registry of the European Society for Pediatric Nephrol-
ogy and the European Renal Association and European
Dialysis and Transplant Association (the ESPN/ERA-EDTA
Registry) aims to increase the amount and quality of
information on children and adolescents on RRT in Europe.6
We therefore aimed to determine (1) the distribution of
blood pressure and prevalence of high blood pressure and
hypertension in the European pediatric RRT population,
(2) the risk factors for high blood pressure, (3) factors
associated with the use of antihypertensive medication,
(4) the evolution of blood pressure over time, and, finally,
(5) the relationship between blood pressure and body mass
index (BMI).
RESULTS
Baseline characteristics
Between 01 January 1999 and 01 January 2010, physicians of
15 countries provided data on 3785 children on RRT to the
ESPN/ERA-EDTA registry. We obtained data on 13,267 blood
pressure measurements from 3337 patients, a median of three
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measurements with a range of 1 to 22 per patient. Mean age
at the initiation of RRT was 11 years and 60.3% were male.
Congenital anomalies of the kidney and urinary tract were
the most frequent underlying disorder. Most children
(55.7%) received PD as their initial treatment modality,
whereas 11% started with a pre-emptive transplantation. At
the time of the blood pressure measurement, 60.6% had a
functional renal graft, whereas 25.5% were on PD and 13.9%
on HD (Table 1). Of all children, 30% started RRT before the
age of 4 years, whereas 21.7% had started RRT when they
were over 13 years of age.
Prevalence of high blood pressure and hypertension
The standard deviation scores (SDSs) of systolic blood
pressure by treatment modality and age groups showed a
higher SDS in the patients on HD (Figure 1). Mean absolute
blood pressure values are presented in Supplementary
Appendix S2. Uncontrolled hypertension, defined as a
systolic or diastolic blood pressure SDS X95th percentile
irrespective of the use of medication, was present in 45.5% of
the HD, 35.5% of the PD, and 21.4% of the transplanted
patients during the course of the study (Figure 2).
Data were available from 10 countries concerning the use
of antihypertensive medication. In these countries, 51.9% of
all patients were using antihypertensive medication (inter-
quartile range 49.3–65.7%). Hypertension, defined as systolic
or diastolic blood pressure X95th percentile or use of
antihypertensive medication, was present in 69.7% of HD,
68.2% of PD, and 66.5% of transplanted patients. Of the
patients treated with antihypertensive medication, 63.8%
of HD patients, 54.6% of PD patients, and 26.6% of
transplanted patients had a blood pressure above the
95th percentile, leaving 26.2% of HD patients, 45.4% of
PD patients, and 73.4% of transplant patients with con-
trolled hypertension. Only 13.9% of HD, 24.9% of PD,
and 24.9% of transplant patients had blood pressures below
the 75th percentile. Among those not treated with anti-
hypertensive medication, 19.8% of HD patients, 21.3% of
Table 1 | Demographic and clinical characteristics population
Variables All (n=3337)
Sex
Male 2015 (60.3)
Female 1322 (39.7)
Age at time of measurement, years
0–3 388 (11.6)
4–12 1201 (36.0)
13–17 1748 (52.4)
Primary renal disease (112 missing)
Glomerulonephritis/sclerosis 451 (13.5)
CAKUT and pyelonephritis 1412 (42.3)
Cystic kidneys 339 (10.2)
Hereditary nephropathy 280 (8.4)
Ischemic renal failure 72 (2.2)
Hemolytic uremic syndrome 129 (3.9)
Metabolic disorder 107 (3.2)
Vasculitis 65 (1.9)
Miscellaneous 162 (4.9)
Unknown/missing 320 (9.9)
Time on RRT at time of measurement, years (166 missing)
0–0.99 329 (10.4)
1–2.99 1092 (34.4)
3–4.99 627 (19.8)
45 1123 (35.4)
Treatment modality at time of measurement
HD 464 (13.9)
PD 851 (25.5)
Tx 2023 (60.6)
Body mass index
o5 percentile 236 (8.8)
20–84 percentile 1642 (61.2)
X85 percentile 807 (30.1)
Abbreviations: CAKUT, congenital anomalies of the kidney and urinary tract; HD,
hemodialysis; PD, peritoneal dialysis; RRT, renal replacement therapy; Tx, transplant.
Data presented as n(%).
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Figure 1 |Unadjusted standard deviation score (SDS) of
systolic blood pressure by treatment modality and age
groups. Box plots show the median, the 25th and 75th percentile,
and the 5th and 95th percentile. SDS X1.65 is equal to the
95th percentile of blood pressure.
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Figure 2 |Distribution of blood pressure percentiles in different
subgroups of patients.
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PD patients, and 5.8% of transplant recipients had a blood
pressure above the 95th percentile, whereas 47.6%, 52.3%,
and 69.5% had blood pressures levels below the 75th
percentile, respectively. Among countries from which data
were available from 1999 through 2009, the prevalence of
hypertension in Europe remained unchanged (56%).
Risk factors for blood pressure X95th percentile or
uncontrolled hypertension
Younger age, a shorter duration of RRT, and being on dialysis
were significantly associated with uncontrolled hyperten-
sion (systolic or diastolic blood pressure X95th percentile;
Figure 3). Furthermore, patients with glomerulonephritis,
hereditary nephropathy, vasculitis, or other known type of
kidney disorders had a twofold increased risk of having
uncontrolled hypertension as compared with patients with
congenital anomalies of the kidney and urinary tract. Nearly,
all factors had similar associations for diastolic and systolic
blood pressure SDS (Table 2). Associations were generally
stronger for systolic blood pressure SDS than for diastolic
blood pressure SDS, because of the mean SDS being lower
for diastolic than systolic blood pressures. As an exception,
however, males had higher diastolic blood pressure SDS as
compared with females, but had similar systolic blood
pressure SDS.
Use of antihypertensive medication
Patients on HD (58.2%) and PD (52.0%) received anti-
hypertensive medication more frequently as compared with
transplanted patients (50.0%). Younger patients receiving
PD (42.3% in the youngest age group) or who had been
transplanted (28.0%) were less often treated with antihyper-
tensive medication compared with older patients (Po0.05).
Furthermore, as compared with patients with congenital
anomalies of the kidney and urinary tract, in whom 42.0%
used antihypertensive medication, patients with vasculitis
(84.0%), hemolytic uremic syndrome (72.6%), and glomer-
ulonephritis (69.0%) used antihypertensive medication
significantly more often. All effects remained significant after
adjustment for potential confounders. There were no
differences in the use of antihypertensive medication between
males and females, nor did we find an association with the
duration of RRT.
Evolution of blood pressure status
We compared the development in blood pressure SDS over
time among children who had a blood pressure o95th
percentile with those who had a blood pressure X95th
percentile in the first 3 months after initiation of the
treatment modality (Figure 4). In children commencing HD
or receiving a transplant with a high blood pressure SDS,
a statistically significant decline in systolic blood pressure
SDS occurred in the first year after initiation of the respective
treatment modality (first year SDS change¼1.3 on HD and
1.7 after transplantation (both Po0.05)). In the children
with a non-elevated blood pressure at initiation of HD or
transplant, blood pressures tended to increase over time.
Among PD patients, blood pressure SDS did not change
significantly over time, irrespective of having a low or high
blood pressure at the start.
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Figure 3 |Odds ratio of having a systolic or diastolic blood pressure standard deviation scores above the 95th percentile in
different age groups, sex, treatment modality, treatment duration, and primary renal disease. All data are adjusted for all other
factors. CAKUT, congenital anomalies of the kidney and urinary tract; GN, glomerulonephritis; HD, hemodialysis; IRF, ischemic renal failure;
PD, peritoneal dialysis; Tx, transplant.
1094 Kidney International (2011) 80, 1092–1098
or ig ina l a r t i c l e AM Kramer et al.: Blood pressure in children on renal replacement therapy
Relation with BMI
In children on HD, a lower BMI was associated with a higher
systolic and diastolic blood pressure SDS (Figure 5). Con-
versely, both diastolic and systolic blood pressure SDS of
transplanted children were higher in children with a higher
BMI (regression coefficient¼ 0.07, Po0.01 per BMI category
increase for systolic blood pressure SDS and regression
coefficient¼ 0.03, Po0.01 per BMI category increase for
diastolic blood pressure SDS).
DISCUSSION
We found a high prevalence of hypertension in European
children on RRT. Very young patients had a significantly
higher blood pressure SDS than older children. HD patients
had the highest blood pressure SDS at onset of therapy, but
over time blood pressure decreased, in contrast to PD
patients in whom blood pressure did not change.
In our dialysis patients, 54.4% had a blood pressure
X95th percentile irrespective of medication use, which is in
line with a US study from Mitsnefes et al.7 who found 56.9%
when using the same definition. However, when the use of
antihypertensive medication was included in the definition of
hypertension, the prevalence of hypertension was 69% in HD
patients and 49.9% in transplant patients. This was much
lower than US population, which showed prevalences of 79%
among HD1 and 58% among transplant patients,8 which
suggests a lower use of antihypertensive medication in
Europe. Two other European studies showed varying results,
finding 55% in Polish dialysis patients3 and 89% in renal
transplant recipients from the Czech Republic.5
Patients younger than 3 years of age had a significantly
higher blood pressure SDS than adolescents. At the same
time, these very young patients on PD had on average a lower
use of antihypertensive drugs as compared with older
children. Furthermore, even though very young children on
HD had the most severe overall degree of hypertension, the
use of antihypertensive medication was no different from
Table 2 | Factors associated with mean blood pressure SDS
Mean systolic
blood pressure SDS
Mean diastolic
blood pressure SDS
Total 1.00 (0.92–1.07) 0.76 (0.70–0.82)
Age (years; adjusted for sex, treatment modality, time on RRT, primary renal
disease)
0–3 1.38 (1.26–1.50)a 1.32 (1.22–1.42)a
4–12 1.09 (1.03–1.15)a 0.78 (0.73–0.83)a
13–18 0.84b 0.63b
Sex (adjusted for age, treatment modality, time on RRT, primary renal disease)
Male 0.99b 0.79b
Female 1.00 (0.92–1.08) 0.71 (0.65–0.78)a
Treatment modality (adjusted for age, sex, time on RRT, primary renal disease)
HD 1.51 (1.41–1.61)a 1.13 (1.05–1.21)a
PD 0.97 (0.89–1.06)a 0.86 (0.79–0.93)a
Tx 0.89b 0.63b
Time on RRT (years; adjusted for age, sex, treatment modality, primary renal
disease)
0–0.99 1.28 (1.16–1.40)a 0.99 (0.90–1.09)a
1–2.99 1.04 (0.96–1.11)a 0.79 (0.72–0.85)a
3–4.99 0.96 (0.89–1.03) 0.75 (0.69–0.81)
X5 0.90b 0.69
Primary renal disease (adjusted for age, sex, treatment modality, time on RRT)
CAKUT and pyelonephritis 0.79b 0.63b
Glomerulonephritis/sclerosis 1.21 (1.09–1.33)a 0.99 (0.90–1.08)a
Cystic kidneys 1.11 (0.98–1.25) 0.80 (0.70–0.91)a
Hereditary nephropathy 1.19 (1.03–1.35)a 0.83 (0.72–0.93)a
Ischemic renal failure 0.97 (0.71–1.22) 0.64 (0.44–0.82)
Hemolytic uremic syndrome 1.14 (0.94–1.33)a 0.88 (0.73–1.03)a
Metabolic disorder 1.05 (0.82–1.33)a 0.78 (0.61–0.96)
Vasculitis 1.45 (1.15–1.74)a 1.04 (0.81–1.27)a
Miscellaneous 1.16 (0.99–1.34)a 0.93 (0.79–1.07)a
Unknown/missing 1.06 (0.87–1.25)a 0.76 (0.60–0.92)
Abbreviations: CAKUT, congenital anomalies of the kidney and urinary tract; HD,
hemodialysis; PD, peritoneal dialysis; RRT, renal replacement therapy; SDS, standard
deviation scores; Tx, transplant.
aSignificantly different from reference population.
bReference group.
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Figure 4 |Changes in mean standard deviation score (SDS)
over time by treatment modality, after start of treatment
modality stratified for the blood pressure (BP) at start.
All patients were required to have at least one measurement
within the first 3 months after start of that treatment modality.
Information was available for 76 hemodialysis (HD) patients, 183
peritoneal dialysis (PD) patients, and 66 transplant (Tx) patients.
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other children on HD. Both findings suggest undertreatment
of hypertension in these very young children. A general
reluctance to prescribe antihypertensive medication in the
absence of information about their safety and efficacy profiles
in this age group might have contributed to these outcomes.
There was a persistent hypertensive status in the PD
population. This is in keeping with a US registry report.9
Blood pressure in HD patients was highest at the onset of
RRT in comparison to PD and transplant patients but
decreased over time, in contrast to the PD group. However,
HD patients with a blood pressure below the 95th percentile
at initiation of HD showed an increase instead of a decrease
of blood pressure over time. Both these trends in PD and HD
patients demonstrate the difficulty of controlling blood
pressure in the dialysis population. One possible explanation
is the difficulty of estimating the dry body weight in a
growing child on dialysis at the moment when residual
diuresis is decreasing and, consequently, the chance of
overhydration is increasing.10 In transplant patients, the
mean blood pressure strongly declined after transplantation,
and was around 1 SDS 1 year post transplantation, irrespec-
tive of whether the patients had high or low blood pressure
initially. The findings in HD and transplant patients suggest a
more adequate treatment of hypertension over time in these
patients. However, certain limitations in this study challenge
such definite conclusions at this point. For instance, the
mean decrease in blood pressure in HD and transplant
patients over time could also partly be explained by the
phenomenon of regression to the mean, as there was selection
based on a single high or low blood pressure measurement.
Second, we could only analyze a limited number of patients
for the follow-up of blood pressure over time and it is not
certain if this sample is representative for the whole
population. Incident patients with three blood pressure
measurements during follow-up were included, of whom the
first measurement had to take place within the first 3 months
after initiation of RRT. We requested only one yearly follow-
up measurement, and only a few incident patients were on a
single treatment for three subsequent years. For example, if a
patient underwent transplantation within 2 years after
initiation of dialysis, he might not have had three reported
measurements while being on dialysis. Nevertheless, this
analysis might give an indication on what is happening on
follow-up, especially among pediatric renal allograft recipi-
ents, as no other information is yet available on this group.
We found remarkably high blood pressure SDS in children
on HD with a low BMI. This is in accordance with data from
the adult population, in which being underweight was
associated with a higher prevalence of hypertension in HD
patients.11 Although we adjusted for age, sex, and primary
renal disease, it seems plausible to assume that the children
who were underweight on HD had more comorbidities as
compared with underweight renal allograft recipients. In
contrast, blood pressure distribution in the transplanted
children was more reflective of findings in the general
pediatric and adult population, showing a higher prevalence
of hypertension in children with obesity.12
There were several limitations to our study, the first of
which is that we did not know how blood pressure was
measured at the participating centers. Failure to standardize
blood pressure measurements across sites could have
introduced errors in the blood pressure measurements.
However, the error in measurements is most likely unrelated
to the ‘real’ presence of hypertension and is almost certainly
unrelated to the analyzed factors. Therefore, this misclassi-
fication will have mainly lead to dilution of the effects found,
resulting in less significant associations between blood
pressure SDS and other factors. More precise measurements
would be expected with ambulatory blood pressure monitor-
ing,13 which has the capacity to reveal white coat hyperten-
sion and masked hypertension and shows a better correlation
with target organ damage such as left ventricular hypertro-
phy. However, this study reflects clinical practice in most
European countries, where office blood pressure measure-
ment is still the mainstay of blood pressure management.
Furthermore, as we found many statistically significant effects
in our study, we believe that the effect of the error was limited.
There was a lack of information with respect to the exact
timing of blood pressure measurements. In general, we
requested pre-dialysis blood pressure readings. Use of pre-
dialysis blood pressure may overestimate blood pressure,
possibly partly explaining the high prevalence of hyperten-
sion in the HD patients as compared with PD patients.
However, Chavers et al.14 found that pre- and post-HD blood
pressures were highly correlated in children on HD and only
in 8% of their population would re-categorization be needed
from hypertensive to normotensive if based on post-dialysis
instead of pre-dialysis blood pressure.
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In conclusion, we demonstrate that, although there is a
lower percentage of hypertension in Europe than in the US,
hypertension is still inadequately treated in a large propor-
tion of European children receiving RRT, as 48.5% of the
children had a blood pressure X95th percentile despite
antihypertensive medication. Hence, our findings highlight
the dimension of the problem of hypertension in children with
end-stage renal disease both before and after transplantation.
MATERIALS AND METHODS
Data collection
For this study, we used data derived from the ESPN/ERA-EDTA
Registry, a large international registry collecting data via national
pediatric registries from 31 European countries, which has been
described previously.6,15 Demographic data obtained during clinical
care included, among others, date of birth, sex, height, weight,
primary renal disease, systolic and diastolic blood pressure, date of
start RRT, use of antihypertensive medication, therapy history, and
treatment modality at the time of measurement.
We included patients whose data were available regarding their
blood pressure or use of antihypertensive medication for the period
from 1999 and onward. This included data from the following
countries and periods: Belarus (2008), the Czech Republic (2007–2008),
Estonia (2009), Finland (1999–2008), Italy (1999–2009, dialysis patients
only), Lithuania (2007–2009), Macedonia (2008–2009), Norway
(2007–2008), Portugal (2007–2008), Romania (2002–2008), Serbia
(2007–2009), Slovakia (2005–2007), Slovenia (2007–2008), Spain
(1999–2009), and the United Kingdom (1999–2009). Information on
the use of antihypertensive mediation was available only for some
of the countries (Belarus, Estonia, Spain, Italy, Lithuania, Norway,
Portugal, Serbia, Slovenia, and Slovakia). Within this population,
information on the use of antihypertensive medication was available
for 94.3% of the patients. To show changes in the prevalence of
hypertension in Europe over time, only those countries were
included for which data were available from 1999 until 2008, namely
Finland, Italy, Spain, and the United Kingdom.
Definition of variables
Blood pressure reference values in children depend on age, height,
and sex and therefore no single cutoff level for hypertension in
children and adolescents can be determined. Following the methods
published in the NHBPEP Fourth report, we calculated systolic and
diastolic blood pressure SDS for each subject, thereby adjusting for
age, sex, and height (heights below 3 SDS were converted into
3 SDS (ref. 16)).
Hypertension was defined as either systolic or diastolic blood
pressure X95th percentile (SDSX1.65) for age, height, and sex or
when using antihypertensive medication, according to the NHBPEP
definitions.17 Patients were excluded if information on the use of
antihypertensive medication was unavailable. Patients with a systolic
or diastolic blood pressureX95th percentile were considered to have
uncontrolled hypertension, irrespective of whether information on
antihypertensive medication was present. The SDS for height, weight,
and BMI were all calculated using the Centers for Disease Control and
Prevention growth charts.18 BMIX85th percentile for age and sex was
defined as overweight, and BMI p5th percentile as underweight.
To determine the development of hypertensive status in each
treatment modality group, we selected only those patients who had
a measurement within the first 3 months after initiation of RRT.
Furthermore, at least three blood pressure measurements needed to
be available in the first 3 years since the initiation of their treat-
ment modality. All patients were required to have at least one
measurement within the first 3 months after initiation of that
treatment modality. Information was available for 76 HD patients,
183 PD patients, and 66 transplant patients.
Renal diseases were grouped by primary renal disease code for
pediatric patients, according to the ERA-EDTA Registry coding
system19 (see Supplementary Appendix S1 online).
Data analysis
Observations of one individual over time are not independent but
correlated.20 Within the 15 European countries participating in this
study, longitudinal data were assembled. To address the fact that a
patient might be hypertensive on some measurements but not
others, and that not all patients had the same number of
measurements, every measurement was divided by the total number
of measurements for that patient. For example, if a patient had one
hypertensive measurement and one normotensive measurement, he
was counted as 1/2 patient in the hypertensive group and 1/2 patient
in the normotensive group.
To calculate unadjusted and adjusted blood pressure SDS, we
performed a linear mixed model analysis. Linear mixed model
analysis allows adjustment for the number of measurements taken
for every individual patient, and simultaneously for different
variables,21 using all of the available information. The relationship
between hypertension and potential correlating variables was
examined and adjustments were made for the following variables:
sex, age, primary renal disease, treatment modality at time of blood
pressure measurement, and time on RRT. Standardized SDS blood
pressure values were recalculated using the distribution of all cases.
To calculate the adjusted values for being on antihypertensive
medication versus not being on antihypertensive medication, we
performed a logistic mixed model analysis, with the same
adjustments as prescribed for the linear mixed model analysis.
Statistical analyses were performed using the SPSS software
version 18.0 (SPSS, Chicago, IL) and SAS 9.2 (SAS Institute,
Cary, NC). P values o0.05 were considered statistically significant.
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Appendix S2. Systolic blood pressure levels by treatment modality
and age groups. Box plots show the median, the 25th and 75th
percentile and the 5th and 95th percentile. The red lines indicate
the cut-off values of hypertension for boys with a mean age
in that particular group with a height at the 25th percentile.
Supplementary material is linked to the online version of the
paper at http://www.nature.com/ki
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